gbola amusa md cfa head hc research
sale trade et
sale trade et
viral news genet medicin zolgensma bla see data integr concern
highlight week august august avexi novarti unrat compani involv data
manipul issu bla file zolgensma gene therapi gt approv treat spinal
muscular atrophi sma accord statement fda issu involv accuraci anim model
data product test use part bla file fda assess situat remain
confid zolgensma remain market novarti issu press releas respond situat
state compani work fda resolv issu impact time futur file
develop zolgensma center medicar medicaid servic announc final
decis cover car-t therapi cancer addit plan work fda nation cancer
institut monitor outcom patient receiv therapi unrat note advers
event report erron submit fda advers event report system faer report indic case
rhabdomyolysi patient sarepta phase ii trial gt duchenn
muscular dystrophi dmd sarepta comment report submit faer sarepta employe
studi princip investig safeti monitor board recommend studi continu uninterrupt
stop rule trigger rhabdomyolysi risk associ dmd unrat
unrat report top-line result broaden phase ii/iii trial antisens
oligonucleotid aso therapeut waylivra treatment famili partial lipodystrophi fpl result show
statist signific reduct triglycerid level compar placebo month post-treat
maintain month hepat fat fraction compar increas placebo month
bluerock privat announc acquir bayer unrat deal expect close
bayer previous own bluerock pay mm up-front mm pre-specifi
mileston acquir remaind compani acquisit bayer full right bluerock cell
gene induc pluripot stem cell ipsc platform bluerock oper independ compani
look forward august august compani report result unrat august
et vbl neutral august et unrat august
market open arcturu buy august et host call discuss
result august et
weekli price move vivo genet medicin aav srna mrna vivo gene edit
upcom chardan genet medicin event contact chardan rsvp
gene express zolgensma data issu show import manufactur
august fda releas statement avexi novarti unrat compani disclos data
manipul issu regard gt zolgensma issu involv accuraci anim model data
product test use part bla file fda note avexi learn data
manipul fda approv zolgensma may notifi fda june per inspect
report alleg origin report march avexi offici open non-conform report
may may alleg data deriv in-vivo rel potenc assay
studi may mismanag even potenti manipul addit gener august
review mous databas note discrep data use calcul
rel potenc lot singl mous surviv day record differ
actual valu significantli data manipul directli impact product releas commerci
pleas refer import disclosur inform regul analyst certif found page report
assay question use commerci product releas zolgensma remain market
fda assess situat
follow releas fda statement novarti issu press releas respons novarti address concern
state remain fulli capabl releas high-qual fulli compliant zolgensma patient need addit
novarti continu work fda resolv issu compani anticip
impact time futur regulatori submiss develop program
note associ zolgensma news manufactur process see broader neg
aav-bas gene therapi space part due evid manufactur leadership issu lack aav-
base gt experi zolgensma avexi acquisit assay question use initi product
test current zolgensma commerci product releas issu relat clinic
evid zolgensma safeti efficaci qualiti look potenti readacross base data
integr concern believ specif zolgensma note avexi use icelli bioreactor use us
less-easili scalabl adher cell cultur oppos more-scal suspension-bas cell cultur system sarepta
therapeut unrat anoth gt compani use icelli bioreactor previous note issu
scalabl manufactur process
buy result give visibl time new ind file august amusa
report result provid updat upcom mileston pipelin asset
along previous announc guidanc initi pivot trial recess dystroph
epidermolysi bullosa rdeb phase i/ii trial autosom recess
congenit ichthyosi arci krystal plan file ind aesthet applic
netherton syndrom us strongli support thesi krystal uniqu platform skin diseas
abu buy pt hbv clinic august naka
arbutu biopharma report result provid corpor updat compani end quarter
cash mm includ mm gross proce sale futur onpattro royalti
buy manag believ cash invest balanc suffici
fund oper
next expect present clinic data phase ia/ib clinic trial evalu hepat viru
hbv capsid inhibitor toward end year arbutu announc preliminari result trial
juli howev given limit data report find difficult draw firm conclus expect learn
much addit data studi report scientif confer later year
arbutu sirna agent target hbv evalu phase ia/ib clinic trial
compani first galnac design sirna deliv subcutan expect
superior potenc durabl compar arbutu discontinu develop
arrowhead report fiscal result highlight recent progress compani current
pre-commerci recogn mm defer revenu reflect quarterli amort mm
up-front payment janssen unrat compani collabor licens agreement rnai
arrowhead reveal posit file cta advanc previous undisclos candid
rnai therapeut aro-hsd target liver hepatocyt cell clinic treat alcohol relat non-alcohol
arrowhead provid initi look data phase studi rnai therapeut aro-
global summit cardiolog heart diseas septemb broader set interim
data studi american heart associ aha confer novemb possibl data
tripl combin cohort phase i/ii studi hbv aasld novemb
buy pt multipl data readout come second half august naka
report result provid corpor updat compani report revenu
mm product sale rnai therapeut onpattro mm sequenti increas
number import potenti catalyst upcom sequenti releas top-line data phase
clinic trial orion evalu rnai therapeut inclisiran treatment hypercholesterolemia
expect report quarter alnylam partner medicin compani buy chardan top pick
page
top-line data phase illuminate-a studi evalu rnai therapeut lumasiran
treatment primari hyperoxaluria type remain track report fda
establish pdufa date februari prioriti review rnai therapeut givosiran treatment
acut hepat porphyria ahp time fda plan hold advisori committe meet discuss
applic
buy ceo place turn clinic ex vivo tx advanc august livshit
edita medicin report result reiter guidanc vivo ex vivo gene edit program catalyst
remaind compani addit announc appoint interim ceo cindi collin ceo
presid edita may reflect slow crispr execut turnov trend though note
search fill perman cfo role edita on-going
compani re-affirmed guidanc across vivo ocular franchis patient dose set begin
phase i/ii brillianc trial vivo crispr therapi leber
congenit amaurosi lead candid usher syndrom type expect readi
ind-en activ
manag yet provid timelin data present compani collabor
bluerock privat ipsc edita disclos intern progress made recent month includ
deriv ipsc fibroblast peripher blood cell gene edit ipsc differenti
ipsc function nk cell
buy piii data trial start august livshit
report result provid updat anticip clinic catalyst cancer-select gene
therapi fc high-grad glioma tumor type compani remain set report data
final analysi pivot phase trial fc recurr high-
grade glioma rhgg
beyond rhgg anticip addit trial initi phase ii/iii trial run
collabor oncolog newly-diagnos hgg phase ib studi non-muscl invas
remain focus key readout keep eye regimen advanc
indic still view rhgg readout potenti binari outcom see opportun fc
succeed base mechan upsid
genet medicin news august august
sln gb unrat announc appoint jrgen wittendorff head manufactur august
unrat announc appoint dr rafael amado evp august
xon unrat announc patient dose pi studi car-t tx solid tumor august
unrat announc fda clearanc ind car-t tx aml bpdcn md august
ancn unrat report result provid corpor updat august
blcm unrat report result provid program updat august
buy announc fda grant prioriti review nda rnai tx givosiran ahp august
ntgn unrat report result provid pipelin updat august
unrat announc appoint mark baldri chief commerci offic august
unrat receiv fda orphan drug design aso tx dravet syndrom august
nv unrat respond fda statement data manipul zolgensma product test august
unrat report result provid busi updat august
unrat announc appoint steve elm board director august
unrat report result provid corpor updat august
unrat announc mm privat placement convert bond august
unrat report result provid busi updat august
page
unrat report unrat result pii/iii studi aso tx waylivra fpl august
akcea ioni report top-line result broaden phase ii/iii trial aso therapeut
waylivra treatment fpl waylivra approv eu may treatment famili
patient administ waylivra placebo via subcutan inject data show reduct
baselin triglycerid level waylivra-tr patient compar reduct placebo-tr patient
month triglycerid lower maintain month post-treat data also show reduct
baselin liver fat waylivra-tr patient compar increas placebo-tr patient
unrat report result highlight recent progress august
cll unrat report result provid corpor updat august
bold buy report result provid pipelin updat august
xcur buy announc appoint dr bali muralidhar bosun hau board director august
unrat report result provid pipelin updat august
selb unrat announc strateg partnership askbio privat next-gen aav august
selecta bioscienc askbio announc strateg partnership develop manufactur
commerci aav-bas partnership leverag selecta immtor platform aim mute
immun respons aav vector thu potenti allow re-dos askbio aav-bas gt platform
unrat report result provid corpor updat august
lentigen privat publish multispecif anti-hiv duocar-t cell human mous model august
buy report result highlight recent clinic develop august
unrat announc fda clearanc ind car-t tx august
unrat report result provid busi updat august
vor biopharma privat announc appoint robert ang presid ceo august
xylocor tx privat announc appoint dr rickey reinhardt august
prqr buy report result provid corpor updat august
buy announc price mm public offer common stock august
announc medicar cover car-t therapi august
center medicar medicaid servic final decis cover car-t therapi
provid healthcar facil enrol fda risk evalu mitig strategi rem per fda label
approv indic would includ hospit well enrol clinic
also plan cover fda-approv car-t off-label use recommend -approv
addit provid access car-t also plan work nation institut health nation
cancer institut nci fda collect data patient characterist advers event outcom patient
unrat report result provid busi updat august
buy report result provid updat aav-bas gt wamd august
unrat report result announc corpor restructur august
unrat report result highlight recent progress august
tng fp unrat provid updat termin piii trial ov pexa-vec august
bluerock tx privat announc acquisit bayer unrat august
bayer acquir bluerock therapeut mm close addit mm achiev pre-
specifi mileston bluerock form joint ventur bayer versant ventur
page
mm seri bayer stake repres bluerock mm repres acquisit cost
remain stake valu bluerock approxim bn acquisit expect close
bluerock remain independ compani oper arms-length basi
bayer plan use bluerock ipsc platform cell gene build capabl cell therapi bluerock
pipelin includ asset neurolog cardiolog immunolog lead program parkinson diseas pd
expect enter clinic
bluerock strateg collabor edita buy provid bluerock non-exclus licens
edita crispr technolog bluerock plan employ technolog develop off-the-shelf cell-bas therapi
indic neurolog cardiolog immunolog note august research recent uptick
news-flow ipsc-bas therapeut us signal build momentum space
selb unrat report result provid busi updat august
unrat report result provid corpor updat august
unrat receiv opinion ema odd veledimex august
autl unrat report result provid oper updat august
unrat report result provid busi updat august
unrat report result provid corpor updat august
xcur buy report result highlight recent develop august
unrat publish unrat result piii trial aso tx waylivra fc august
ortx unrat report result note upcom regulatori file august
neutral report result provid corpor updat august
buy announc patient dose pii/iii trial rnai tx aro-aat august
unrat report result provid oper updat august
neutral report result provid busi updat august
buy report result highlight recent progress august
dynacur privat receiv fda orphan drug design aso tx cnm august
unrat report result highlight recent develop august
rgl unrat report result provid busi updat august
unrat report result highlight recent accomplish august
unrat report result provid corpor updat august
unrat comment error submiss fda advers event report august
sarepta comment advers event report erron submit fda advers event
report system faer sarepta comment report submit faer sarepta employe
studi princip investig
report indic case rhabdomyolysi patient sarepta phase ii trial
gt duchenn muscular dystrophi dmd accord report week post-treat patient
present dark color urin elev creatin phosphokinas ck level patient hospit
discharg next day test result return baselin
studi placebo control unclear patient treatment placebo arm sarepta note
rhabdomyolysi commonli understood risk associ duchenn muscular dystrophi
sarepta princip investig remain blind studi safeti monitor board review un-blind
data recommend studi continu uninterrupt
xon unrat report result provid busi updat august
neutral report result provid corpor updat august
buy report result highlight recent progress august
unrat report result provid busi updat august
page
unrat report result highlight recent develop august
compani mention report
page
select catalyst genet medicin coverag
dose patient phase studi mp
provid updat phase i/ii studi hemophilia
dcr-phxc initi long-term registr roll-ov studi ph
aro-aat initi phase ii/iii studi liver diseas
lumasiran initi illuminate-c phase trial
file ind pomp diseas
inclisiran report top-line data orion studi hypercholesterolemia
initi phase i/ii clinic trial huntington diseas
initi phase ii trial /- cemiplimab cutan squamou cell carcinoma
initi phase trial /- solid tumor
initi phase i/ii trial dmd nationwid children hospit
report interim efficaci readout phase oval trial ovarian cancer
report dose escal data pi/ii trial achm/xlrp
dcr-hbv anticip first interim data clinic trial hbv
provid initi data phase trial gangliosidosi
provid initi data phase trial gangliosidosi
axo-lenti-pd report data cohort sunrise-pd phase ii trial
submit ind methylmalon acidemia mma
present data phase portion solid tumor trial /- nivolumab
provid earli data cohort phase i/ii pioneer trial n- rp
file ind phase ii studi diabet retinopathi dr
present interim data pi/ii studi mp ii pi studi mp
present interim data cohort steroid prophyl pi/ii studi hofh
file ind batten diseas
top-lin phase ii data treat deb patient chronic wound
initi phase i/ii trial autosom recess congenit ichthyosi
initi dose phase trial hemophilia
provid updat priorit program sjogren syndrom al wet
initi patient dose brillianc phase i/ii trial
initi phase iib studi wet
lumasiran present top-line data illuminate-a phase trial
vutrisiran initi helios-b phase studi cardiomyopathi attr amyloidosi
inclisiran file nda hypercholesterolemia
file ind huntington diseas program
 fc initi phase ii/iii trial newli diagnos glioblastoma
 fc safeti activ readout phase ib trial met solid tumor
present preclin data new gt program fabri pomp defici
provid follow-up data piib dose-confirm studi hemb
file ind cta pomp diseas
present top-lin data phase i/iia clinic trial wet
 fc report final analysi phase trial rhgg
declar develop candid aml
initi phase trial dystroph epidermolysi bullosa deb
figur alnylam/mdco meiragtx replimun solid uniqur expect import data read-out
page
select catalyst outsid genet medicin coverag
nsr-rpgr provid prelim data expans cohort phase ii/iii trial xlrp
dtx provid phase i/ii cohort data ornithin transcarbamylas defici
dtx provid pi/ii cohort data glycogen storag diseas type ia gsdia
initi eu phase ii studi fanconi anemia
zolgensma anticip approv eu
nsr-rpgr report follow-up data open label dose escal phase xiriu studi
valrox submit bla pend fda feedback hemophilia
initi pivot phase trial rdeb
initi phase data patient leukocyt adhes deficiency-i lad-i
report initi phase data process fanconi anemia
suvodirsen interim data open-label extens studi dmd
initi phase studi pyruv kinas defici pkd
initi us phase ii studi fanconi anemia
begin dose patient investigator-sponsor phase i/ii trial cystinosi
initi phase i/ii trial type gaucher diseas
bmn file ind phenylketonuria pku
initi phase ib trial beta-thalassemia
initi phase i/ii trial parkinson diseas mutat
initi phase trial multipl myeloma
initi clinic trial charcot-marie-tooth type
file approv transit clinic trial platform manufactur
rituximab report preliminari phase cohort expans data r/r nhl
micro-dystrophin initi pivot trial duchenn muscular dystrophi
initi phase ii studi overact bladder
initi phase i/ii trial gangliosidosi
zolgensma complet strong phase trial pre-symptomat sma type
initi phase i/ii studi best diseas
micro-dystrophin initi confirmatori trial commerci materi dmd
begin patient dose phase trial
initi phase trial recess dystroph epidermolysi bullosa
nsr-rpgr provid follow-up data phase xiriu dose escal studi xlrp
file ind inherit amyotroph later sclerosi
tegsedi expect approv brazil hattr amyloidosi
 anticip data readout phase trial hd
ptc-aadc file bla aromat l-amino acid decarboxylas aadc defici
ptc-fa file ind friedreich ataxia fa enter clinic
sea-bcma report preliminari phase dose escal data r/r mm
lentiglobin initi phase studi sickl cell diseas
zynteglo initi roll bla submiss fda tdt
report initi data phase i/ii trial phenylketonuria pku
figur plan file bla aadc defici
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ adhera therapeut
benitec biopharma fibrocel buy lysogen oncosec medic oxford biomedica buy vbl neutral
figur select price movement week end august vivo gm perform aav srna mrna ivg
page
week-over-week perform vivo genet medicin aav srna mrna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm adverum genet therapytickerratingccm ptupsideclosechang changemc mm alnylam gene editingtickerratingccm ptupsideclosechang changemc mm sangamo pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note though avx nite acquir continu includ exhibit reflect valu creation sub-sector
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur srna mrna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap cap million srna mrna gt sector market cap cap million vivo gene edit sector market cap
aav-bas gene therapi comp meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy buy qure buy greater potenti drive upsid aav gt space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog privat aav-bas genetherapi molecular ask estev horama stride tamid
srna mrna therapi comp alnylam top pick
corpor report factset chardan note mention stock unrat unless state target market cap unrat name model current market cap
figur select public srna mrna therapi companiesw prefer buy buy greater potenti drive upsid entir srna mrna space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat srna mrna therapi companiesadvirna silense sirnaom somagen sylenti ntech curevac ethri etherna immunotherapi genev scienc strand note adhera benitec pharma silenc addit
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiesbeam egenesi excis exon feldan recombinet
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
price prv
page
date fda rpdd
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
crispr vertex
crispr vertex
parkinson diseas mutat
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
date fda ftd
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
parkinson diseas mutat
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
